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Objectives The aim of this study was to assess the impact of early and late bleeding on subse-
quent mortality after drug-eluting stent (DES) implantation.
Background Little is known about the impact of late bleeding after DES implantation.
Methods With a time-updated Cox model, the impact of bleeding and myocardial infarction (MI) on
3-year mortality was analyzed in 3,148 consecutive patients who underwent DES implantation for
coronary disease.
Results Bleeding, deﬁned according to STEEPLE (Safety and Efﬁcacy of Enoxaparin in PCI Patients,
an International Randomized Evaluation) minor or major criteria, occurred in 6.5% of patients over 3
years. Patients with bleeding were older; were more likely to be female; had higher rates of diabetes
mellitus, hypertension, and extensive coronary disease and lower ventricular function; and under-
went more complex procedures than those without bleeding. The 3-year adjusted hazard ratios
(HRs) for mortality were 5.81 (95% conﬁdence interval [CI]: 3.92 to 8.60; p  0.001) for patients with
leeding and 2.53 (95% CI: 1.62 to 3.96; p  0.001) for patients with MI. When the timings of events
were separated, the HRs for mortality were 4.89 (95% CI: 3.08 to 7.78; p  0.001) and 7.81 (95% CI:
4.39 to 13.89; p  0.001) for patients with bleeding within and after 30 days, respectively. By con-
trast, the HRs for mortality were 1.85 (95% CI: 1.09 to 3.14, p  0.022) and 10.33 (95% CI: 4.91 to
21.75, p  0.001) for patients with MI within and after 30 days, respectively.
Conclusions Bleeding is closely associated with mortality during both the early and late periods after
DES implantation. Therefore, in addition to carefully assessing bleeding after stenting, evidence-based
treatment should be implemented to offer the best balance of beneﬁt and harm. (J Am Coll Cardiol
Intv 2011;4:423–31) © 2011 by the American College of Cardiology Foundation
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424Advancements in pharmaceutical agents have improved the
outcomes of patients undergoing percutaneous coronary
intervention (PCI) for coronary artery disease. In particular,
drug-eluting stents (DES) have reduced rates of restenosis
and the subsequent need for repeat revascularization com-
pared with bare-metal stents. However, long-term dual
antiplatelet therapy with aspirin and clopidogrel is required
to prevent the late occurrence of stent thrombosis, although
it increases the risks of bleeding (1). The incidence of
bleeding complications is higher in patients treated with
clopidogrel plus aspirin than in those treated with aspirin
alone (2). Bleeding, in turn, has been associated with an
increased risk of mortality (3–7). Most studies of bleeding
complications and mortality, however, have focused on the
effects of early bleeding related directly to the procedure in
patients with acute coronary syndrome (ACS), with few
studies assessing the association between bleeding compli-
cations and late mortality. Therefore, we assessed the
impact of bleeding on early and late mortality in patients
undergoing DES implantation in daily practice. Further-
more, the relative risks of mortality among patients with
bleeding were compared with
those among patients with myo-
cardial infarction (MI) during
each period.
Methods
Population. The study popula-
tion consisted of all patients who
received at least 1 DES for cor-
onary artery stenosis between
February 2003 and February
006 at 2 centers in Korea (8). Patients who underwent
oronary brachytherapy were excluded. The institutional
eview board of each hospital approved the study, and
nformed consent was obtained from all patients. The
uthors had full access to the data and take full responsibility
or their integrity. All authors have read and agree to the
anuscript as written.
Procedure and data collection. Stenting procedures were
erformed according to general guidelines (9). Because our
rotocol did not specify the method of stenting, the use of
ntravascular ultrasound or any other adjunctive coronary
evice was at the discretion of the operator. During the
tudy period, DES was the default stent in both institutions
or patients with coronary artery stenosis, but the choice of
ES was at the discretion of each operator. Each patient
as administered a loading dose of 200 mg aspirin and 300 mg
lopidogrel before the procedure. During the procedure, a single
olus (100 U/kg) and subsequent boosters (2,000 U) of heparin
ere injected to achieve an activated clotting time 250 s.
dministration of glycoprotein IIb/IIIa inhibitor before or during
Abbreviations
and Acronyms
ACS  acute coronary
syndrome
CI  confidence interval
DES  drug-eluting stent(s)
HR  hazard ratio
MI  myocardial infarction
PCI  percutaneous
coronary interventionhe procedure was at the discretion of the physician. After DES cmplantation, standard dual antiplatelet therapy, consisting of 100
g/day aspirin and 75 mg/day clopidogrel, was recommended for
t least 6 months, with a longer period of clopidogrel use
ecommended for patients at high risk of ischemic complications.
atients at high risk of ischemic events were also administrated
ilostazol 200 mg/day for 1 month after stenting at the discretion
f the physician (10).
Baseline and procedural information was collected into a
edicated database by independent research nurses. All
atients were followed-up by office visit or telephone con-
act at 1 month and 6 and 12 months after the procedure
nd every 6 months thereafter. To validate complete
ollow-up data, information about vital records was obtained
rom the National Registration System of the Ministry of
overnment Administration and Home Affairs in Korea with
personal identification number. In addition, data regarding
epeat hospital stay for follow-up MI were obtained from the
ospital Disease Code Registration system.
Endpoints and deﬁnitions. The primary end point was the
ccurrence of any-cause mortality. Myocardial infarction
as diagnosed by the presence of ischemic symptoms or
igns plus cardiac enzyme elevation (creatine kinase-muscle
rain elevation 3 or creatine kinase elevation 2 the
upper limit of normal). Among all MIs, small MI was
defined as elevation of creatine kinase-muscle brain eleva-
tion 8 the upper limit of normal. Major and minor
bleeding were defined as described in STEEPLE (Safety
and Efficacy of Enoxaparin in PCI Patients, an Interna-
tional Randomized Evaluation) (11). Major bleeding was
defined as fatal bleeding; retroperitoneal, intracranial, or
intraocular bleeding; bleeding that caused hemodynamic
compromise requiring specific treatment; bleeding that
required intervention (surgical or endoscopic) or decom-
pression of a closed space to stop or control the event;
clinically overt bleeding; requirement for any transfusion
of1 U packed red cells or whole blood; and clinically overt
bleeding causing a decrease in hemoglobin of 3 g/dl (or if
hemoglobin level not available, a 10% decrease in hemat-
ocrit). Minor bleeding was defined as bleeding that did not
meet any of the criteria of major bleeding and that met at
least 1 of the following criteria: gross hematuria not asso-
ciated with trauma; epistaxis that was prolonged, repeated,
or required plugging or intervention; gastrointestinal hem-
orrhage; hemoptysis; subconjunctival hemorrhage; hema-
toma 5 cm or leading to prolonged or new hospital stay;
clinically overt bleeding causing a decrease in hemoglobin of
2 to 3 g/dl; and uncontrolled bleeding requiring protamine
sulfate administration. The cause and time of events were
independently adjudicated on the basis of the source docu-
ments. When the cause of bleeding was not certain, the date
of bleeding was declared when the clinically overt bleeding
was identified or blood component was transfused.
Statistical analysis. Patient baseline characteristics and pro-
edural findings were presented by mean SD and number
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425(percentage). All patients were censored at the time of an
event or at a fixed interval of 3 years. Time-to-event was
assessed by the Kaplan-Meier incidence curves, which were
compared with the log-rank test. Differences in baseline
Table 1. Baseline and Procedural Characteristics of
Post-Procedure
Bleeding (n  207)
Clinical features
Age, yrs 63.9 9.9
Male 131 (63.3)
Hypertension 129 (62.3)
Smoking 48 (23.2)
Hypercholesterolemia 42 (20.3)
Diabetes mellitus 76 (36.7)
Chronic renal failure 18 (8.7)
Prior PCI 19 (9.2)
Prior CABG 8 (3.9)
Acute MI 44 (21.3)
Stable angina 99 (47.8)
Unstable angina 64 (30.9)
LV ejection fraction, % 56.1 10.3
Baseline hemoglobin, g/dl 12.4 2.1
Baseline platelet, 103/mm3 226.6 91.4
Angiographic features
Multivessel disease 141 (68.1)
2 vessels 62 (30.0)
3 vessels 76 (36.7)
Left main involvement 3 (1.4)
ACC/AHA type B2/C 168 (81.2)
Bifurcation lesion 40 (19.3)
Restenotic lesion 7 (3.4)
Chronic total occlusion 7 (3.4)
Procedures
Use of IVUS 115 (55.6)
Multiple DES 120 (58.0)
Number of DES 2.2 1.4
Total length of DES, mm 54.8 37.1
Multivessel PCI 85 (41.1)
Glycoprotein IIb/IIIa inhibitor 16 (7.7)
Medication at discharge
Warfarin 7 (3.4)
Statin 95 (45.9)
Beta blocker 138 (66.7)
Calcium channel blocker 140 (67.6)
ACE inhibitor 61 (29.5)
Cilostazol 69 (33.3)
Dual antiplatelet therapy†
At 6 months 172 (83.1)
At 1 yr 66 (31.9)
Values are mean SD or n (%) unless otherwise indicated.
*The p values were drawn by univariate Cox models. †Dual antiplatel
ACC/AHA  American College of Cardiology/American Heart Asso
coronary artery bypass graft; CI  confidence interval; DES  drug-emyocardial infarction; PCI percutaneous coronary intervention.clinical, angiographic, and procedural characteristics be-
tween groups of patients with and without bleeding were
compared with the univariate Cox proportional hazard
models. To separately evaluate the impact of early and late
ts With and Without Bleeding 3 Years
eding (n  2,941) HR (95% CI) p Value*
60.3 10.3 1.03 (1.02–1.05) 0.001
2,091 (71.1) 0.71 (0.54–0.95) 0.02
1,463 (49.7) 1.64 (1.24–2.17) 0.001
868 (29.5) 0.73 (0.53–1.01) 0.058
714 (24.3) 0.81 (0.58–1.14) 0.23
786 (26.7) 1.54 (1.16–2.04) 0.003
62 (2.1) 4.06 (2.50–6.59) 0.001
521 (17.7) 0.48 (0.30–0.77) 0.002
76 (2.6) 1.46 (0.72–2.96) 0.29
391 (13.3) 1.77 (1.27–2.47) 0.001
1,420 (48.3)
1,130 (38.4)
58.6 8.7 0.97 (0.96–0.99) 0.001
13.4 1.7 0.77 (0.71–0.82) 0.001
229.0 63.0 0.999 (0.997–1.002) 0.54
1,717 (58.4) 1.51 (1.12–2.02) 0.006
948 (32.2)
709 (24.1)
60 (2.0) 0.72 (0.47–1.12) 0.15
2,319 (78.9) 1.15 (0.81–1.62) 0.45
575 (19.6) 0.98 (0.70–1.39) 0.20
216 (7.3) 0.45 (0.21–0.95) 0.037
206 (7.0) 0.47 (0.22–1.00) 0.050
2,047 (69.6) 0.56 (0.42–0.73) 0.001
1,548 (52.6) 1.14 (0.93–1.62) 0.14
1.9 1.1
47.6 30.5 1.01 (1.00–1.01) 0.001
966 (32.8) 1.41 (1.07–1.86) 0.015
77 (2.6) 3.13 (1.88–5.21) 0.001
22 (0.7) 4.02 (1.89–8.54) 0.001
1,597 (54.3) 0.72 (0.55–0.95) 0.018
2,219 (75.5) 0.66 (0.49–0.88) 0.004
2,237 (76.1) 0.66 (0.49–0.88) 0.005
847 (28.8) 1.03 (0.76–1.38) 0.87
800 (27.2) 1.33 (0.99–1.77) 0.056
2,565 (87.2) 1.41 (0.98–2.03) 0.063
1,008 (34.3) 1.12 (0.84–1.50) 0.45
py includes aspirin and clopidogrel.
lesion classification; ACE  angiotensin converting enzyme; CABG 
tent(s); IVUS  intravascular ultrasound; LV  left ventricular; MI Patien
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426bleeding on mortality after the procedure, we compared event
curves for patients with and without bleeding and for bleeding
that occurred within or after 30 days of stent implantation.
Multivariable Cox proportional hazard models were developed
to identify the independent predictors of 3-year bleeding and
MI with covariates having p values 0.1. The multivariable
odel considered 19 potential covariates: age, sex, hyperten-
ion, smoking history, diabetes mellitus, chronic renal failure,
ypercholesterolemia, prior history of PCI or coronary artery
ypass graft, left ventricular ejection fraction, acute myocardial
nfarction, multivessel disease, multivessel PCI, multiple DES,
se of glycoprotein IIb/IIIa inhibitor, use of warfarin or statin
t discharge, baseline hemoglobin, and platelet count. The
roportional hazards assumption was confirmed by examina-
ion of log (-log [survival]) curves and by testing of partial
Schoenfeld) residuals, and no relevant violations were found.
Furthermore, to investigate the interactive impact of MI and
leeding on mortality, a time-updated Cox model was created
ith adjustment of the aforementioned covariates (12). To
urther estimate the time-dependent risk of major bleeding and
I on mortality rate, additional Cox models were developed
ith different time-updated binary covariates for discrete time
ntervals (i.e., 0 to 30 days and31 days after the event) which
Figure 1. Incidence Curves of EventsThree-year Kaplan-Meier curves of adverse events in patients with and without bleedre clinical relevant point. All reported p values are 2-sided,
nd p values 0.05 were considered statistically significant.
he SAS software (version 9.1, SAS Institute, Cary, North
arolina) was used for all statistical analyses.
esults
Baseline and procedural characteristics. Of the 3,160 pa-
tients who underwent DES implantation at the 2 institu-
tions between February 2003 and February 2006 (8), informa-
ion on bleeding complications was available for 3,148 patients.
able 1 shows their baseline and procedural characteristics.
ompared with patients without bleeding, those with bleeding
t 3 years were more likely to be female and of advanced age
nd to have hypertension, diabetes mellitus, chronic renal
ailure, MI at presentation, low ventricular ejection fraction,
ow hemoglobin, and extensive coronary artery disease. There-
ore, patients with bleeding were more likely to be treated with
ultiple stents and glycoprotein IIb/IIIa inhibitors. Dual
ntiplatelet therapy with aspirin and clopidogrel was adminis-
ered to 87% of patients at 6 months and 34% at 1 year and was
imilar between the 2 groups.
Unadjusted outcomes. Figure 1 shows the Kaplan-Meiering events.
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427incidences of adverse outcomes for 3 years. Figure 2 shows
the separate incidences of events within 30 days and 30 days
after procedure. Although the occurrence of bleeding and
MI were mostly clustered within 30 days after DES implan-
tation, there were some incidences of bleeding after 30 days,
mostly within 1 year. The incidence of mortality gradually
increased over the 3-year study period. Figure 3 shows that the
mortality rates were higher in patients with than without
bleeding, both within 30 days and after 30 days post-
procedure. Over 3 years, 134 patients died with cardiac (71
patients) and noncardiac (63 patients) causes. Bleeding by 3
years occurred in 207 patients comprising 123 major and 84
minor episodes. The causes of bleeding according to the
STEEPLE criteria were listed in Table 2. After bleeding, 8
(3.9%) patients experienced MI (median of 127 days, inter-
quartile range 6 to 496 days) and 31 (15.0%) patients died
(median of 262 days, interquartile range 54 to 490 days). At the
time of bleeding, 113 (54.6%) were receiving dual antiplatelets
including aspirin plus clopidogrel, and 77 (37.2%) were receiv-
ing triple antithrombotics, including dual antiplatelets with
either cilostazol in 51 or warfarin in 26. After bleeding
episodes, 40 (19.3%) patients discontinued all antithrombotic
medications. Myocardial infarction at 3 years occurred in 204
patients, including 97 (47.5%) patients having a small MI
(CK-MB8 the upper normal limit). Definite angiographic
stent thrombosis occurred in 31 patients (median of 386 days,
Figure 2. Incidence Curves of Events After 30 Days Post-Procedure
Three-year Kaplan-Meier curves of adverse events in patients with and withouinterquartile range 18 to 623 days).Independent predictors of bleeding or MI. Table 3 shows the
independent predictors of bleeding and MI. We found that
advanced age, hypertension, chronic renal failure, the first PCI,
low ejection fraction, anemia, acute MI at presentation, mul-
tivessel PCI, and use of glycoprotein IIb/III inhibitor or
warfarin were independent predictors of bleeding.
Adjusted hazard ratios for mortality. Figure 4 shows the
djusted hazard ratios (HRs) and 95% confidence intervals
CIs) for mortality among patients with bleeding or MI.
hen the incidences of bleeding were separated according
o the timing of events, the HRs for mortality were
ignificantly higher in patients with than without bleeding,
oth within and after 30 days. These findings were similar in
atients who had suffered an MI (Fig. 5). When bleeding
vents were separated, both major (HR: 11.10; 95% CI: 7.42 to
6.62; p 0.001) and minor (HR: 2.10; 95% CI: 1.06 to 4.16;
 0.033) bleedings were significantly associated with 3-year
ortality after adjustment. The occurrence of small MI also
ncreased the adjusted risk of 3-year mortality (HR: 2.32; 95%
I: 1.43 to 3.76; p  0.001).
iscussion
Our results indicate that bleeding complications in pa-
tients undergoing DES implantation for coronary artery
stenosis was associated with a 6-fold increased risk of
ing events occurring within and after 30 days post-procedure.death over 3 years. Although two-thirds of bleeding
g eve
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428complications occurred within 30 days after the proce-
dure, the remaining one-third occurred after 30 days,
mostly within 1 year. The association between bleeding
and subsequent death was consistently observed, both
during the early and late periods after stenting, as
Figure 3. Incidence Curves of Events Within After 30 Days Post-Procedure
Three-year Kaplan-Meier curves of deaths in patients with and without bleedin
Table 2. Causes of Bleeding Events According to the STEEPLE Definitions
Overall 207
Retroperitoneal bleeding 3 (1.4%)
Intracranial bleeding 2 (1.0%)
Bleeding in the closed space 3 (1.4%)
Genitourinary bleeding 4 (1.9%)
Prolonged epistaxis 2 (1.0%)
Gastrointestinal bleeding 28 (13.5%)
Hemoptysis 3 (1.4%)
Vascular access complication 52 (25.1%)
Bleeding related to repeat revascularization 5 (2.4%)
Bleeding related with noncardiac surgery 13 (6.3%)
Bleeding related with cancer 7 (3.4%)
Clinically overt bleeding causing hemoglobin drop or
transfusion
85 (41.1%)STEEPLE Safety andEfficacyof Enoxaparin in PCI Patients, an International RandomizedEvaluation.indicated by the increased risks of mortality among
patients with bleeding within and after 30 days.
nts occurring (A) within 30 days and (B) after 30 days post-procedure.
Table 3. Multivariate Predictors of 3-Year Bleeding and MI
Bleeding MI
HR 95% CI p Value HR 95% CI p Value
Age, yrs 1.02 1.01–1.04 0.002 — — —
Hypertension 1.42 1.06–1.90 0.018 — — —
Previous PCI 0.52 0.32–0.84 0.007 — — —
Chronic renal failure 1.93 1.12–3.31 0.018 2.40 1.34–4.31 0.003
LV ejection fraction, % 0.98 0.97–0.996 0.011 — — —
Acute MI 1.56 1.09–2.23 0.016 — — —
Baseline hemoglobin, g/dl 0.84 0.77–0.90 0.001 — — —
Multivessel PCI 1.35 1.02–1.79 0.034 — — —
Multivessel disease — — — 1.82 1.29–2.56 0.001
Glycoprotein IIb/IIIa
inhibitor
3.30 1.97–5.51 0.001 2.22 1.26–3.90 0.006
Warfarin 3.03 1.42–6.49 0.004 — — —
Multiple stents — — — 1.88 1.36–2.60 0.001Abbreviations as in Table 1.
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429Several clinical trials have shown that bleeding complications
increased the risk of mortality during treatment for acute coronary
syndrome (3–7). A recent analysis of the ACUITY (Acute
Catheterization and Urgent intervention Triage strategy) trial of
patients with ACS showed that the occurrence of bleeding within
30 days post-procedure increased the 1-year mortality risk 3.5-
fold, whereas the occurrence of MI within 30 days increased the
1-year mortality risk 3.1 (3). The GRACE registry (Global
Registry of Acute Coronary Events) of ACS patients also reported
that in-hospital bleeding complications increased mortality risk
1.9-fold (4). Nevertheless, the long-term clinical impact of time of
bleeding has not been well-evaluated, and most previous studies
limited enrollment to patients with ACS (3–7). Therefore, our
study had the advantages of enrolling all patients treated with
DES and its extended clinical follow-up.
We found that, over 3 years, bleeding complication occurred in
approximately 7% of patients who underwent DES implantation
for coronary artery stenosis. Because bleeding was closely related
with procedural complication, two-thirds of bleeding episodes
occurred within 30 days after the procedure. Mortality was less
closely related with procedures, and 47% of the deaths during
follow-up were noncardiac deaths. The rate of periprocedural
bleeding at 30 days was lower than in studies enrolling patients
with ACS but similar to studies of patients treated with PCI
(3–7,13). The incidences of bleeding, in fact, were dependent on
patient risk profiles, treatment strategies, assessment times, and
Figure 4. Adjusted Hazard Ratios With Covariates, Bleeding, and MI
Adjusted with covariates, bleeding, and myocardial infarction (MI) for 3-year m
taneous coronary intervention.definitions. Of the various definitions of bleeding, we adopted theSTEEPLE criteria, because others—such as Thrombolysis in
Myocardial Infarction and GUSTO (Global Use of Strategies to
Open Coronary arteries) bleeding criteria (14,15)—primarily fo-
cused on severe and moderate bleeding during early stages
of treatment (16). Bleeding criteria focusing on periproce-
dural events might underscore the importance of long-term
bleeding, because the severity of bleeding in the late period
after PCI seems to differ (17).
The increased risk of death among patients who developed
bleeding remained evident after adjustment for baseline and
procedural characteristics with time-updated Cox models, in
agreement with previous studies showing an association between
bleeding and subsequent death (3–7). Death after bleeding epi-
sodes might be due to hypotension, anemia, the adverse effects of
blood product transfusion, ineffective oxygen delivery, vasocon-
striction, platelet dysfunction, or—in some patients—the discon-
tinuation and/or reversal of essential antithrombotic or antiplatelet
therapy (18,19). By contrast, death after MI after PCI might be
due to distal embolization, side branch occlusion, flow limiting
dissection, or vasospasm in the early period or to a thromboem-
bolic event, fatal arrhythmia, or pump failure in the late period
(20,21).
Our study highlighted the long-term clinical impact of
bleeding beyond 30 days post procedure on mortality.
Although there are few studies evaluating the impact of late
bleeding after DES implantation, the GRACE registry,
y with the time-updated Cox model. CI  conﬁdence interval; PCI  percu-ortalitconducted before the introduction of DES, showed that
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430patients with bleeding after discharge were not at increased
risk of mortality compared with patients without bleeding
(4). Likewise, pooled data from 3 large studies, which
included 34,146 patients with ACS, suggested that the
association of bleeding after 30 days post-procedure with
subsequent death was not strong (7). Although an analysis
from the ACUITY trial showed an association between
bleeding within 30 days and 1-year mortality, the impact of
late bleeding was not evaluated (3,5). By contrast, we found
that the hazard for death among patients with bleeding after
30 days was not lower than that among those with bleeding
within 30 days. Moreover, the risk of death after bleeding
was similar to the risk of death after MI, both within and
after 30 days. A recent large dataset supported our finding
that bleeding after discharge increases the risk of 1-year
death or MI after PCI in elderly patients (22). However, the
data were limited due to the selective inclusion of elderly
patients 65 years of age and heterogeneous inclusion of
CI with either bare-metal stent or DES (22).
The mechanisms linking bleeding and subsequent death
ight be more complicated in the late than in the early
eriod. Prolonged use of dual antiplatelet therapy, consist-
ng of aspirin and clopidogrel, after DES implantation
ight contribute, at least in part, to the occurrence of late
leeding. We found that 87% and 34% of our patients
emained on dual antiplatelet therapy at 6 months and 1
Figure 5. Adjusted Hazard Ratios Within and After 30 Days
Adjusted for 3-year mortality among patients with MI or bleeding within and
Cox model. Abbreviations as in Figure 4.ear, respectively. By contrast, in the PREMIER study(Prospective Registry Evaluating Myocardial Infarction:
Events and Recovery), which compared the patterns of
antiplatelet medication after discharge among patients with
acute MI, approximately 40% of patients remained on
thienopyridine at 6 months (19). In the randomized CURE
(Clopidogrel in Unstable Angina to Prevent Recurrent Events)
trial, the incidence of major bleeding was higher among
patients taking dual antiplatelet therapy than those taking
aspirin alone (2). Moreover, results of the CHARISMA
(Clopidogrel for High Atherothrombotic Risk and Ischemic
Stabilization, Management, and Avoidance) trial suggested
that dual antiplatelet therapy might paradoxically increase
morality in asymptomatic patients, via an unknown mech-
anism (23). More recently, dual antiplatelet therapy over 1
year was found to increase the risk of bleeding, (24) but not
reduce the incidence of ischemic events (24,25). We found
that the incidences of bleeding and subsequent death were
negligible after 1 year post-procedure, when fewer patients
were adherent to dual antiplatelet therapy. Alternatively,
discontinuation of dual antiplatelet therapy after bleeding
might potentially contribute to death through recognized or
unrecognized thrombotic episodes.
Study limitations. First, although we used rigorous statisti-
cal adjustment, unmeasured confounders might have influ-
enced the outcomes. For example, patients at high risk of
ischemic complications might have been prescribed a more
0 days, compared with those without MI or bleeding, with the time-updatedafter 3intensive regimen of antiplatelet agents, for a longer period,
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431which might have increased the risk of bleeding complica-
tion. Second, a merge of major and minor criteria into the
definition of bleeding might overestimate the strength of
hazard. Conversely, however, the current definition of major
bleeding might underestimate the true impact of bleeding
on clinical outcomes, especially in the late period after PCI.
Third, because the definition of MI included periprocedural
enzyme elevation with any ischemic symptom, the relative
impact of MI on death might have been diluted. Fourth,
owing to the limited numbers of subjects and events,
complicated interactions among adverse events could not be
determined. Therefore, the plausible mechanisms linking
the events of bleeding and death could not be completely
evaluated. Large-scale studies are needed to assess the causal
relationships among bleeding, MI, and subsequent death.
Conclusions
Our results indicate that bleeding complications in the early and
late periods after DES placement are closely associated with death.
Therefore, in addition to carefully assessing bleeding complica-
tions after stenting, evidence-based medical treatment should be
implemented after PCI to offer the best balance between benefit
and harm, thus optimizing patient outcomes.
Reprint requests and correspondence: Dr. Seung–Jung Park,
Department of Cardiology, Heart Institute, University of Ulsan
College of Medicine, Asan Medical Center, 388–1 Poongnap–
dong, Songpa– gu, Seoul, 138 –736 South Korea. E-mail:
sjpark@amc.seoul.kr.
REFERENCES
1. Kushner FG, Hand M, Smith SC, et al. Focused updates: ACC/AHA
guidelines for the management of patients with ST-elevation myocar-
dial infarction (updating the 2004 guideline and 2007 focused update)
and ACC/AHA/SCAI guidelines on percutaneous coronary interven-
tion. J Am Coll Cardiol 2009;54:2205–41.
2. Yusuf S, Zhao F, Mehta SR, et al. The Clopidogrel in Unstable Angina
to Prevent Recurrent Events Trial I. Effects of clopidogrel in addition
to aspirin in patients with acute coronary syndromes without ST-
segment elevation. N Engl J Med 2001;345:494–502.
3. Mehran R, Pocock SJ, Stone GW, et al. Associations of major
bleeding and myocardial infarction with the incidence and timing of
mortality in patients presenting with non–ST-elevation acute cor-
onary syndromes: a risk model from the ACUITY trial. Eur Heart J
2009;30:1457– 66.
4. Spencer FA, Moscucci M, Granger CB, et al. Does comorbidity
account for the excess mortality in patients with major bleeding in acute
myocardial infarction? Circulation 2007;116:2793–801.
5. Pocock SJ, Mehran R, Clayton TC, et al. Prognostic modeling of
individual patient risk and mortality impact of ischemic and
hemorrhagic complications. Assessment from the Acute Catheter-
ization and Urgent Intervention Triage Strategy Trial. Circulation
2009;121:43–51.
6. Manoukian SV, Feit F, Mehran R, et al. Impact of major bleeding on 30-day
mortality and clinical outcomes in patients with acute coronary syndromes: an
analysis from the ACUITY trial. J Am Coll Cardiol 2007;49:1362–8.
7. Eikelboom JW, Mehta SR, Anand SS, Xie C, Fox KAA, Yusuf S.
Adverse impact of bleeding on prognosis in patients with acute
coronary syndromes. Circulation 2006;114:774–82.8. Park DW, Yun SC, Lee SW, et al. Stent thrombosis, clinical events,
and influence of prolonged clopidogrel use after placement of
drug-eluting stent data from an observational cohort study of
drug-eluting versus bare-metal stents. J Am Coll Cardiol Interv
2008;1:494 –503.
9. Smith SC Jr., Feldman TE, Hirshfeld JW Jr., et al., American College
of Cardiology/American Heart Association Task Force on Practice
Guidelines; ACC/AHA/SCAI Writing Committee to Update the
2001 Guidelines for Percutaneous Coronary Intervention. ACC/
AHA/SCAI 2005 guideline update for percutaneous coronary inter-
vention. J Am Coll Cardiol. 2006;47:e1–121.
10. Lee SW, Park SW, Hong MK, et al. Triple versus dual antiplatelet
therapy after coronary stenting: impact on stent thrombosis. J Am Coll
Cardiol 2005;46:1833–7.
11. Montalescot G, White HD, Gallo R, et al. Enoxaparin versus
unfractionated heparin in elective percutaneous coronary intervention.
N Engl J Med 2006;355:1006–17.
12. Altman DG, De Stavola BL. Practical problems in fitting a propor-
tional hazards model to data with updated measurements of the
covariates. Stat Med 1994;13:301–41.
13. Steinhubl SR, Berger PB, Mann-Iii JT, et al. Early and sustained dual
oral antiplatelet therapy following percutaneous coronary intervention:
a randomized controlled trial. JAMA 2002;288:2411–20.
14. Rao AK, Pratt C, Berke A, et al. Thrombolysis in Myocardial
Infarction (TIMI) Trial—phase I: hemorrhagic manifestations and
changes in plasma fibrinogen and the fibrinolytic system in patients
treated with recombinant tissue plasminogen activator and streptoki-
nase. J Am Coll Cardiol 1988;11:1–11.
15. The GUSTO investigators. An international randomized trial compar-
ing four thrombolytic strategies for acute myocardial infarction. N Engl
J Med 1993;329:673–82.
16. Waksman R. Definition, incidence, correlates, and clinical impact of
“Nuisance” bleeding in patients undergoing drug-eluting stent implan-
tation. Am J Cardiol 2009;104 Suppl 1:30C–3C.
17. Rao SV, Eikelboom J, Steg PG, et al. Standardized reporting of
bleeding complications for clinical investigations in acute coronary
syndromes: a proposal from the Academic Bleeding Consensus (ABC)
Multidisciplinary Working Group. Am Heart J 2009;158:881–6.
18. Manoukian SV. Predictors and impact of bleeding complications in
percutaneous coronary intervention, acute coronary syndromes, and
ST-segment elevation myocardial infarction. Am J Cardiol 2009;104
Suppl 1:9C–15C.
19. Wang TY, Xiao L, Alexander KP, et al. Antiplatelet therapy use after
discharge among acute myocardial infarction patients with in-hospital
bleeding. Circulation 2008;118:2139–45.
20. Ricciardi MJ, Wu E, Davidson CJ, et al. Visualization of discrete
microinfarction after percutaneous coronary intervention associated
with mild creatine kinase-MB elevation. Circulation 2001;103:2780–3.
21. Brener SJ, Lytle BW, Schneider JP, Ellis SG, Topol EJ. Association between
CK-MB elevation after percutaneous or surgical revascularization and three-
year mortality. J Am Coll Cardiol 2002;40:1961–7.
22. Ko DT, Yun L, Wijeysundera HC, et al. Incidence, predictors, and
prognostic implications of hospitalization for late bleeding after percu-
taneous coronary intervention for patients older than 65 years. Circ
Cardiovasc Interv 2010;3:140–7.
23. Wang TH, Bhatt DL, Fox KAA, et al. An analysis of mortality rates
with dual-antiplatelet therapy in the primary prevention population of
the CHARISMA trial. Eur Heart J 2007;28:2200–7.
24. Diener PH-C, Bogousslavsky PJ, Brass PLM, et al. Aspirin and
clopidogrel compared with clopidogrel alone after recent ischaemic
stroke or transient ischaemic attack in high-risk patients (MATCH):
randomised, double-blind, placebo-controlled trial. Lancet 2004;364:
331–7.
25. Park SJ, Park DW, Kim YH, et al. Duration of dual antiplatelet
therapy after implantation of drug-eluting stents. N Engl J Med
2010;362:1374–82.
Key Words: bleeding  mortality  myocardial infarction 
stent.
